Lupin Receives U.S. FDA Approval for Risperidone Long-Acting Injectable, with 180-Day CGT Exclusivity, the First Product from its Nanomi's Long-Acting Injectable Platform

Lupin Limited Austria Belgium France Germany Italy Netherlands Spain Switzerland United Kingdom United States of America

or follow us on LinkedIn https://www.linkedin.com/company/lupin

To know more about Nanomi, visit www.nanomi.com or follow on LinkedIn https://www.linkedin.com/company/nanomi

*Safe Harbor Statement

Risperdal Consta® is a registered trademark of Johnson & Johnson.

Logo: https://mma.prnewswire.com/media/2461104/Lupin_Logo.jpg

 

 

View original content:https://www.prnewswire.co.uk/news-releases/lupin-receives-us-fda-approval-for-risperidone-long-acting-injectable-with-180-day-cgt-exclusivity-the-first-product-from-its-nanomis-long-acting-injectable-platform-302552541.html